Combining methionine‐PET and MRI fluid‐attenuated inversion‐recovery mismatch to determine glioma molecular subtype
Journal of Neuroimaging · 2023
DOI: 10.1111/jon.13114 ↗At a glance
Journal article in Journal of Neuroimaging, 2023. Written by Kazufumi Ohmura and 7 co-authors. Institution: Chubu Medical Center for Prolonged Traumatic Brain Dysfunction, Minokamo, Japan. Major MEDLINE topics: Brain Neoplasms, Glioma. Cited 4 times so far (Crossref); 20 references.
Abstract (original language)
Background and Purpose 11 C‐methionine (MET)‐PET is a useful tool in neuro‐oncology. The T2‐fluid‐attenuated inversion recovery (FLAIR) mismatch sign on MRI is a characteristic finding in lower grade gliomas with isocitrate dehydrogenase (IDH) mutations and the absence of the 1p/19q codeletion; however, the T2‐FLAIR mismatch sign has low sensitivity in differentiating gliomas and does not aid in identifying glioblastomas with IDH mutations. We therefore investigated the efficacy of the combination of the T2‐FLAIR mismatch sign and MET‐PET for accurately determining the molecular subtype of gliomas of all grades.
Methods
The present study comprised 208 adult patients diagnosed with supratentorial glioma confirmed by molecular genetics and histopathology. The ratio of the maximum lesion MET accumulation to the mean normal frontal cortex MET accumulation (T/N) was measured. The presence or absence of the T2‐FLAIR mismatch sign was determined. The presence or absence of the T2‐FLAIR mismatch sign and the MET T/N ratio were compared between glioma subtypes to evaluate individual and combined utility in identifying gliomas with IDH mutations and no 1p/19q codeletion (IDHmut‐Noncodel) or gliomas with IDH mutations (IDHmut).
Results
The addition of MET‐PET to MRI for the presence of the T2‐FLAIR mismatch sign improved diagnostic accuracy, with the area under the curve values increasing from .852 to .871 for IDHmut‐Noncodel and from .688 to .808 for IDHmut.
Conclusions
The combination of the T2‐FLAIR mismatch sign and MET‐PET may provide improved diagnostic utility in differentiating gliomas according to molecular subtype, particularly in determining IDH mutation status.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Chubu Medical Center for Prolonged Traumatic Brain Dysfunction, Minokamo, Japan.
- Department of Neurosurgery, Gifu University Graduate School of Medicine, Gifu, Japan.
- Chubu Neurorehabilitation Hospital, Minokamo, Japan.
- Department of Clinical Brain Sciences, Gifu University Graduate School of Medicine, Minokamo, Japan.
- Center for Advanced Medical Engineering Research and Development (CAMED), Kobe University Graduate School of Medicine, Kobe, Japan.
- Department of Neurosurgery, Tokyo Women's Medical University, Shinjuku, Japan.
ORCID profiles: Kazufumi Ohmura
Cite
APA
Ohmura, K., Kumagai, N., Kumagai, M., Ikegame, Y., Shinoda, J., Yano, H., Muragaki, Y., & Iwama, T. (2023). Combining methionine‐PET and MRI fluid‐attenuated inversion‐recovery mismatch to determine glioma molecular subtype. Journal of Neuroimaging. https://doi.org/10.1111/jon.13114
Vancouver
Ohmura K, Kumagai N, Kumagai M, Ikegame Y, Shinoda J, Yano H, et al. Combining methionine‐PET and MRI fluid‐attenuated inversion‐recovery mismatch to determine glioma molecular subtype. Journal of Neuroimaging. 2023. doi:10.1111/jon.13114
BibTeX
@article{Ohmura2023,
author = {Ohmura, Kazufumi and Kumagai, Nobutoshi and Kumagai, Morio and Ikegame, Yuka and Shinoda, Jun and Yano, Hirohito and Muragaki, Yoshihiro and Iwama, Toru},
title = {Combining methionine‐PET and MRI fluid‐attenuated inversion‐recovery mismatch to determine glioma molecular subtype},
journal = {Journal of Neuroimaging},
year = {2023},
doi = {10.1111/jon.13114}
}
EUVIMED